Anthem Biosciences Ltd Technical Momentum Shifts Signal Mildly Bullish Outlook

Technical Trend Overview and Price Movement

On 29 June 2026, Anthem Biosciences closed at ₹761.15, down 1.19% from the previous close of ₹770.30. The intraday range was relatively tight, with a low of ₹760.00 and a high of ₹775.40. The stock remains comfortably above its 52-week low of ₹579.45 but still trails its 52-week high of ₹873.25, indicating room for recovery and growth potential.

The recent technical trend adjustment from bullish to mildly bullish suggests a tempering of upward momentum, possibly reflecting profit-taking or consolidation after prior gains. This shift is critical for investors to monitor, as it may signal a period of sideways movement or a cautious advance rather than a strong rally.

MACD and Momentum Indicators

The Moving Average Convergence Divergence (MACD) indicator remains bullish on the weekly timeframe, signalling that the medium-term momentum is still positive. However, the monthly MACD does not currently provide a clear signal, indicating that longer-term momentum is less decisive. This divergence between weekly and monthly MACD readings suggests that while short-term traders may find opportunities, longer-term investors should remain vigilant for confirmation of sustained trends.

RSI and Overbought/Oversold Conditions

The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no definitive signal. This neutral RSI reading implies that the stock is neither overbought nor oversold, which aligns with the mildly bullish technical stance. The absence of extreme RSI values reduces the likelihood of an imminent sharp reversal, but also indicates a lack of strong buying pressure at present.

Moving Averages and Bollinger Bands

Daily moving averages for Anthem Biosciences are mildly bullish, suggesting that short-term price averages are trending upwards, albeit modestly. This is supported by the weekly Bollinger Bands, which also indicate a mildly bullish outlook, reflecting moderate volatility and a tendency for prices to remain within a defined range. Monthly Bollinger Bands, however, do not show a strong directional bias, reinforcing the view of a cautious market environment.

Additional Technical Signals: KST, Dow Theory, and OBV

The Know Sure Thing (KST) indicator is bullish on both weekly and monthly timeframes, signalling positive momentum across multiple periods. This is a favourable sign for investors looking for confirmation of upward trends. Meanwhile, Dow Theory assessments are mildly bullish on both weekly and monthly charts, indicating that the broader market trend for Anthem Biosciences is cautiously optimistic but not yet robust.

On-Balance Volume (OBV) analysis shows no clear trend on the weekly chart but a mildly bullish trend on the monthly chart. This suggests that while short-term volume flows are indecisive, longer-term accumulation may be occurring, which could support future price appreciation.

Comparative Performance Against Sensex

Anthem Biosciences has outperformed the Sensex significantly on a year-to-date basis, delivering a 16.91% return compared to the Sensex’s negative 9.53%. This strong relative performance highlights the stock’s resilience amid broader market weakness. However, over the past week, the stock declined by 4.62%, considerably more than the Sensex’s modest 0.40% drop, indicating short-term volatility and possible profit-booking.

On a monthly scale, the stock’s return was slightly negative at -0.49%, while the Sensex gained 0.80%. Longer-term data is unavailable for the stock, but the Sensex’s 3-year and 5-year returns of 22.42% and 45.68% respectively provide a benchmark for sector and market expectations.

Mojo Score and Analyst Ratings

MarketsMOJO assigns Anthem Biosciences a Mojo Score of 71.0, categorising it as a Buy with a mid-cap market cap grade. This represents a significant upgrade from a previous Sell rating as of 21 May 2026, reflecting improved technical and fundamental outlooks. The upgrade underscores growing investor confidence and the potential for further gains, supported by the technical indicators discussed.

Investment Implications and Outlook

The mildly bullish technical stance suggests that investors should approach Anthem Biosciences with cautious optimism. The weekly MACD and KST indicators provide encouraging signs of momentum, but the neutral RSI and mixed monthly signals advise prudence. The stock’s recent underperformance relative to the Sensex in the short term may offer a buying opportunity for those with a medium-term horizon, especially given the strong year-to-date gains and positive Mojo Score upgrade.

Investors should monitor key support levels near ₹760 and resistance around the 52-week high of ₹873.25. A sustained break above this high could signal a return to stronger bullish momentum, while a drop below recent lows may indicate further consolidation or correction.

Sector Context and Broader Market Considerations

Within the Pharmaceuticals & Biotechnology sector, Anthem Biosciences’ technical profile is reflective of a mid-cap stock navigating a complex market environment. The sector has faced headwinds from regulatory scrutiny and global supply chain challenges, yet continues to attract investor interest due to innovation and growth prospects.

Anthem’s technical indicators, particularly the bullish weekly MACD and KST, suggest it is better positioned than some peers to capitalise on sector recovery. However, the mildly bullish Dow Theory signals and neutral OBV readings caution that volume-driven confirmation is still needed to sustain a robust uptrend.

Investors should weigh these technical signals alongside fundamental factors such as earnings growth, pipeline developments, and regulatory updates to form a comprehensive view.

Conclusion

Anthem Biosciences Ltd’s recent technical parameter changes reveal a stock in transition, with momentum shifting from strong bullishness to a more tempered mildly bullish stance. The mixed signals from MACD, RSI, moving averages, and volume indicators highlight the importance of close monitoring for confirmation of trend direction.

While short-term volatility may persist, the stock’s year-to-date outperformance and upgraded Mojo Grade to Buy provide a positive backdrop for investors with a medium-term perspective. Careful attention to support and resistance levels, combined with sector dynamics, will be crucial in navigating the stock’s next phase.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →